All News
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Babies! Safety and Outcomes Data on Pregnancies
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.
Read Article
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) prese
Read Article
Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?
Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.
Read Article
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
Are wearable devices useful in assessing physical activity in rheumatic diseases?
Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps.
@RheumNow #EULAR2022 POST#POS0163
Robert B Chao, MD doctorRBC ( View Tweet)
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
David Liew drdavidliew ( View Tweet)
Can genetics solve all the world's problems with predicting response to therapy in rheumatology?
No - but maybe it can be a part of the solution?
Multi-domain apporaches (including good clinical data) needed to really have cut-through
@karolinskainst OP0267 #EULAR2022 @RheumNow https://t.co/wISPUB6m64
David Liew drdavidliew ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR Recommendations for ANCA Vasculitis
Dr. Eric Dein reviews the session held on updates to recommendations for ANCA Vasculitis, presented at the #EULAR2022 meeting in June.
https://t.co/1nr0tVIJpn https://t.co/kq0Id7PxyW
Links:
Dr. John Cush RheumNow ( View Tweet)
Great meeting @RheumNow. He does a great job of educating Rheumatologists around the world especially through his podcast. Great discussion on the usefulness of ultrasound for Rheumatologists #EULAR2022 https://t.co/0hw7mpX8dm
Dr Qasim Akram (South Manchester Rheumatologist) DrQasimAkram ( View Tweet)
Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk
Richard Conway RichardPAConway ( View Tweet)
Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/86e93ugoBQ
TheDaoIndex KDAO2011 ( View Tweet)
Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients
💉APLS is NOT a risk factor for thrombotic AEs with vaccination
#EULAR2022 @Rheumnow @rheum_covid
Eric Dein ericdeinmd ( View Tweet)
“One of the benefits of #vaccinations people don’t talk about is the relief they feel after vaccination."
- Dr E Hyrich #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2
Links:
Richard Conway RichardPAConway ( View Tweet)
Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drhectorchinoy @MarcinMilchert and many others. Significant geographic differences, highlighting need for consensus guidelines @RheumNow #EULAR2022 OP0161 https://t.co/osaORtgvxh https://t.co/96PypMtlcl
Links:
Richard Conway RichardPAConway ( View Tweet)
What does avacopan mean for sustained remission in AAV?
New post-hoc from ADVOCATE - keeping in mind the avacopan was instead of steroids. Impressive numbers, so increasingly the questions will be about strategy and cost?
#EULAR2022 @RheumNow https://t.co/B4y8jZiHf5
David Liew drdavidliew ( View Tweet)
Mortality after PMR:
looking at 35y follow-up of a cohort in Norway,
apparent higher mortality for women (vs men, general population) decades after.
Is this real? Treatment related?
My wild guess: sarcopenia kills.
Thoughts @Sarah_L_Mackie & tagged?
OP0181 #EULAR2022 @RheumNow https://t.co/k7p9jNfW5s
David Liew drdavidliew ( View Tweet)
Sometimes hear “GCA associated with PMR is extracranial”
Interesting point:
of the 20% of PMR patients with USS-evident subclinical GCA
- one-quarter had isolated cranial disease
GCA phenotypes not so clear cut
(Proviso: it’s subclinical disease)
OP0184 #EULAR2022 @RheumNow https://t.co/storHFL8aW
David Liew drdavidliew ( View Tweet)
